Krónikus limfoid leukémia (CLL): vizsgálatok itt: Kína
48 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Where
- Bengbu, Changsha, Guangzhou, Shanghai, Tianjin, Wuhan, Zhanjiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 344 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06319456 · EU 2024-514084-26-00 - Korai 1. fázisTaking peopleA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Where
- Tianjin, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 28
- Run by
- Grit Biotechnology
See details and how to joinNCT07205315 - 2. fázisNot yet taking people in KínaZanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0
- Where
- Changsha, Jinan, Nanchang, Nanjing, Shenzhen, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 60
- Run by
- Yi Shuhua
See details and how to joinNCT07682415 - 2. fázisTaking peopleA Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07671378 - 2. fázisTaking peopleA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Where
- Beijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- Életkor
- 18 év and over
- People
- 66
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT07154264 - 3. fázisTaking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Beijing, Binzhou, Chenzhou, Foshan, Fuzhou, Guangzhou, Hefei, Luzhou, Nanchang, Nanjing, Nanning, Suzhou, Taiyuan, Wuhan, Wuxi, Xi'an, Yibin, Zhengzhou
- Életkor
- 18 év to 99 év
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00 - 3. fázisTaking peopleA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
- Where
- Nanjing, Tianjin
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT07139873 · EU 2025-522669-32-00 - 2. fázisTaking peopleDZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
- Where
- Beijing, Changchun, Dalian, Guangzhou, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 155
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT06539182 - 1. fázisNot yet taking people in KínaU96-CAR-T-Cells For R/R B-ALL
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 30
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07511426 - 2. fázisTaking peopleStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Where
- Guangzhou, Haikou, Hanzhou, Nanchang, Suzhou, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 75
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT05147467 - No phaseNot yet taking people in KínaA Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
- Where
- Langfang
- Életkor
- 18 év to 75 év
- People
- 69
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07476378 - Korai 1. fázisTaking peopleClinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 3
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06890494 - 2. fázisTaking peopleVenetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
- Where
- Nanjing
- Életkor
- 18 év to 80 év
- People
- 79
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06958705 - 2/3. fázisTaking peopleICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Where
- Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Jining, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Ürümqi, Wuhan, Xiamen, Xi'an, Yibin, Yichang, Zhengzhou, Zhenzhou, Zunyi
- Életkor
- 18 év to 80 év
- People
- 226
- Run by
- Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06378138 - 1. fázisTaking peopleSafety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 44
- Run by
- CytoCares Inc
See details and how to joinNCT06037018 - 2. fázisNot yet taking people in KínaPhase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
- Where
- Changchun
- Életkor
- 18 év and over
- People
- 30
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07003464 - No phaseTaking peopleIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Where
- Hefei
- Életkor
- 3 év and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06961669 - 1/2. fázisTaking peopleStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Zhenzhou
- Életkor
- 18 év and over
- People
- 123
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT04494503 - No phaseNot yet taking people in KínaJY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- He Huang
See details and how to joinNCT06902025 - 1/2. fázisTaking peopleCAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
- Where
- Beijing
- Életkor
- 14 év to 75 év
- People
- 20
- Run by
- Affiliated Hospital to Academy of Military Medical Sciences
See details and how to joinNCT06834529 - Korai 1. fázisTaking peopleCD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 20
- Run by
- Zhejiang University
See details and how to joinNCT06346912 - No phaseTaking peopleCD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Where
- Tianjin
- Életkor
- 3 év to 18 év
- People
- 60
- Run by
- Zhu Xiaofan
See details and how to joinNCT06355739 - 2. fázisTaking peopleA Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT03980002